Cerity Partners LLC Purchases Shares of 31,919 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Cerity Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 31,919 shares of the biopharmaceutical company’s stock, valued at approximately $1,773,000.

Other large investors have also made changes to their positions in the company. UMB Bank n.a. lifted its position in shares of Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Ultragenyx Pharmaceutical by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock valued at $853,000 after acquiring an additional 434 shares during the last quarter. KBC Group NV grew its holdings in shares of Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 506 shares in the last quarter. Amalgamated Bank increased its position in Ultragenyx Pharmaceutical by 13.4% in the second quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 696 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth $33,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on RARE shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. HC Wainwright lifted their target price on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, Barclays cut their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. This trade represents a 7.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $47.60 on Tuesday. The firm has a market cap of $4.40 billion, a P/E ratio of -7.36 and a beta of 0.58. The firm’s 50 day moving average price is $51.84 and its 200-day moving average price is $48.75. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm’s revenue was up 42.3% compared to the same quarter last year. During the same quarter last year, the company posted ($2.23) EPS. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.